#ACR24 - Day 3 Report Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations. https://t.co/Dif4EUi30b https://t.co/4hfEJ1ef73

Health Literacy: the forgotten social determinant of health? Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/686bWffD2z https://t.co/TFyzgJ3NeL

JAK inhibitors in GCA? We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg

Highlights in axSpA Dr. Marina Magrey discusses highlights in axSpA from the first day at #ACR24 https://t.co/LvvmzlXWw7 https://t.co/thf9MiMo32

ANCA Vasculitis "Eye": Can rituximab help? Dr. Janet Pope discusses abstract 0726 at #ACR24 https://t.co/KzYcmjon8D https://t.co/KDIi1vJE4P

RA Treatment Adherence: Is decision making really shared? Dr. Jonathan Kay interviews Dr. Cécile Gaujoux-Viala about abstract 0360 at #ACR24. https://t.co/KwXHutfQko https://t.co/bCVM3JrFEz

Treat-to-Target Improves Fertility in Women with RA Dr. Richard Conway discusses abstract 1647, presented at #ACR24 https://t.co/vC0CA0lN4M https://t.co/Dfo7iBYwcU

GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24 https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii

ORAL Surveillance - Is Statin Use the Problem/Solution? The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate. https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd

#ACR24: What Exactly do JAKs and TYKs Do? Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD

Addressing CV Risk in RA: Are we doing enough? The increased risk of cardiovascular disease in patients with rheumatoid arthritis has long been known (1). #ACR24 https://t.co/dajYuK8rpd https://t.co/2Ds3OZEjUX

Apremilast Benefits and Risks in PsA Dr. Akhil Sood discusses abstracts 1466, 2583, 0598 and 2640 discussing the use of apremilast in PsA, presented at #ACR24. https://t.co/SSEeR9Xt9B https://t.co/cUeSUQoRsO